MEDXF - Medexus and medac ink licensing agreement for treosulfan in Canada

Medexus Pharmaceuticals ([[MEDXF]]) announces that it has entered into a licensing agreement with medac GmbH to commercialize treosulfan, a bifunctional alkylating agent, in Canada.Treosulfan will be marketed in Canada under the brand name Trecondyv and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.Medexus will be responsible for selling and marketing the product, while medac will be responsible for the manufacturing and supply.Medexus also said that it is preparing for the launch of treosulfan in the U.S. with the Prescription Drug User Fee Act date approaching on August 11.

For further details see:

Medexus and medac ink licensing agreement for treosulfan in Canada